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Abstract
Background: There is need for the Uganda Ministry of Health to understand predictors of primary health care
pharmaceutical expenditure among districts in order to guide budget setting and to improve efficiency in
allocation of the set budget among districts.
Methods: Cross sectional, retrospective observational study using secondary data. The value of pharmaceuticals
procured by primary health care facilities in 87 randomly selected districts for the Financial Year 2011/2012 was
collected. Various specifications of the dependent variable (pharmaceutical expenditure) were used: total
pharmaceutical expenditure, Per capita district pharmaceutical expenditure, pharmaceutical expenditure per district
health facility and pharmaceutical expenditure per outpatient department visit. Andersen’s behaviour model of health
services utilisation was used as conceptual framework to identify independent variables likely to influence health care
utilisation and hence pharmaceutical expenditure. Econometric analysis was conducted to estimate parameters of
various regression models.
Results: All models were significant overall (P < 0.01), with explanatory power ranging from 51 to 82 %. The log linear
model for total pharmaceutical expenditure explained about 80 % of the observed variation in total pharmaceutical
expenditure (Adjusted R2 = 0.797) and contained the following variables: Immunisation coverage, Total outpatient
department attendance, Urbanisation, Total number of government health facilities and total number of Health Centre
IIs. The model based on Per capita Pharmaceutical expenditure explained about 50 % of the observed variation in per
capita pharmaceutical expenditure (Adjusted R2 = 0.513) and was more balanced with the following variables:
Outpatient per capita attendance, percentage of rural population below poverty line 2005, Male Literacy rate, Whether
a district is characterised by MOH as difficult to reach or not and the Human poverty index.
Conclusions: The log-linear model based on total pharmaceutical expenditure works acceptably well and can be
considered useful for predicting future total pharmaceutical expenditure following observed trends. It can be used as a
simple tool for rough estimation of the potential overall national primary health pharmaceutical expenditure to guide
budget setting. The model based on pharmaceutical expenditure per capita is a more balanced model containing
both need and enabling factor variables. These variables would be useful in allocating any set budget to districts.
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Background
Like all public sector health services in Uganda, pharma-
ceuticals are funded by the Government of Uganda
(GoU) through taxes and donor contributions; and pro-
vided free of charge to clients at the public sector pri-
mary health care (PHC) facilities. Government funding
for essential medicines is through National Medical
Stores VOTE 116, an account established by the govern-
ment to effectively and efficiently supply essential medi-
cines and medical supplies to public sector health
facilities. The VOTE 116 account is the main financing
mechanism for essential medicines and health supplies
(EMHS) for public sector health facilities in Uganda.
Based on a budget that is set by the Ministry of Finance,
districts are allocated funds from this account. The
funds are managed by National Medical Stores (NMS), a
Ministry of Health (MoH) parastatal in charge of pro-
curement, storage and distribution of health commod-
ities. The NMS is mandated by MOH to procure
pharmaceuticals on the National Essential Medicines
list for the delivery of the minimum essential health
care package as defined by the MOH and to pursue
cost containment measures such as procurement of
generic medicines only. With approval of the District
Health Administrations, health facilities routinely order
pharmaceuticals from the NMS against their allocated
budget [1].
Over the last five years, the GoU’s expenditure on
essential medicines and health supplies has grown at a
higher rate than has public health care expenditure.
GoU’s expenditure on EMHS increased substantially
from about 20 billion Uganda shillings (UGX) in the fi-
nancial year (FY) 2009/2010 to about 85 billion UGX in
the FY 2013/2014; a 325 % increase [2]. Despite the in-
crease, current funding for medicines is still below what
is required. A policy options analysis conducted in 2010
revealed that overall government funding for EMHS in
Uganda was insufficient. With the exception of contra-
ceptives and medicines for Tuberculosis all other cat-
egories of pharmaceuticals had significant funding gaps
[3]. The Health Sector Strategic and Investment plan
(HSSIP) 2010/11 - 2014/15 estimated that about 956 bil-
lion UGX was required to cover national needs for
medicines and related health commodities (insecticide
Treated Nets, reproductive health commodities, labora-
tory supplies, indoor residual spraying, vaccines) in FY
2012/13 [4]. However, through VOTE 116, the govern-
ment of Uganda provided an allocation of 219 billion
UGX for the financial year, thereby covering just over
20 % of the estimated national need [2]. This situation
requires keen attention to the predictors of primary
health care pharmaceutical expenditure by districts in
Uganda and the way the set pharmaceutical budget is
allocated to the districts.
There is need for the Uganda Ministry of Health to
understand predictors of primary health care pharma-
ceutical expenditure among districts in Uganda in order
to guide negotiations for potential national budgets and
to improve efficiency in allocation of the set budget
among districts based on need. Identifying the predictors
of pharmaceutical expenditure in public sector health fa-
cilities in the various districts can help identify current
inefficiencies in pharmaceutical expenditure and to iden-
tify factors which if modified, for example, through pol-
icy measures (e.g. training of health workers, improving
staffing etc.) can help contain pharmaceutical expend-
iture or make current spending more efficient by ensur-
ing that the set budget is allocated based on need.
Study goal
For the GoU’s publicly funded EMHS program to be
sustainable in the long term, it is important that poten-
tial influencers of pharmaceutical expenditures are iden-
tified, and that the degree of their influence on such
expenditures is established. This study attempts to ad-
dress this need. The goal of this study is thus to identify
predictors of primary health care pharmaceutical ex-
penditure by districts in Uganda, establish explanatory
models of such expenditure based on the potential influ-
ence of the identified predictors and discuss implications
for potential national pharmaceutical budget estimation
and setting; and allocation of the set budget to the vari-
ous districts by the government.
Prior studies
Studies in Spain, England and Italy have shown socio-
demographic structure, morbidity of the population,
variables associated with health care utilization [5–9],
location and organizational factors [10] and quality of
prescriptions [8] to be associated with pharmaceutical
expenditure in PHC services at the health care area level.
These factors condition the demand and supply of
health services and the accompanying pharmaceutical
expenditure.
With the specific aim of aiding budget setting, Forster
and Frost attempted to explain differences in prescribing
rates and costs between family practitioner committee
areas in England and Wales based on step wise Regres-
sion [9]. They concluded that 60 % of the variation in
prescribing costs per patient could be explained by dif-
ferences in the age/sex distribution of the population,
standardized mortality rates and the supply of general
practitioners (GP) per head of population. Levels of
deprivation (measured by the Jarman index) were also
considered but were found to be unimportant. Similar
results were obtained using number of prescriptions per
person rather than cost per person as the dependent
variable. As part of a more general analysis of practice
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variation in primary care, Baker and Klein examined
differences in GP prescribing rates across family health
services authorities (FHSA). Using step wise regression
analysis, they were able to explain 69 % of variation in
prescribing rates [10]. Explanatory variables found to be
important were similar to those in Forster and Frost’s
study: standardized mortality ratios, the supply of GPs
per capita and the proportion of the population aged
over 65 years [9]. An additional variable, the number of
ancillary staff per practitioner was found to be positively
significant. Again, the Jarman index was not significant.
The literature carries ample evidence of attempts at
identifying and evaluating the effect of determinants of
pharmaceutical expenditure in various contexts. Some
studies have used information on individual patient
characteristics and morbidities using adjusted clinical
groups (ACG) case-mix [11, 12]. Others have used ag-
gregate sales data on hospital sales and dispensed drugs
in ambulatory care, including both reimbursed expend-
iture and patient co-payment; adjusting for factors likely
to increase or decrease future utilization and expend-
iture, such as patent expiries, new drugs to be launched
or new guidelines from national bodies or the regional
drug and therapeutics committees [13].
However such evaluations, in most cases, focus on a
single category of predictors (e.g. need, demographics or
policy factors) and are mainly in developed country con-
texts in which medicines are provided through health in-
surance. Additionally, most studies have used individual
pharmaceutical expenditure data collected through sur-
veys or from individual medical records. Such data is not
readily available in many developing country contexts.
There remains a need for a more inclusive approach
to identifying key influencers or predictors of pharma-
ceutical expenditures using readily available data, and
for assessing their usefulness in explaining pharmaceut-
ical expenditure and guiding pharmaceutical budget set-
ting and allocation in developing countries like Uganda.
Using regression analysis, this paper examines various
models to explain observed variations in pharmaceutical
expenditure at the district level in Uganda; with recom-
mendations for models to be used for rough national




This was a cross sectional, retrospective observational
study using secondary administrative data.
Conceptual framework
The study uses Andersen’s behaviour model of health
services utilization as a conceptual framework. Andersen’s
model was developed to study determinants of acute care
health services utilisation and has since been used fre-
quently in a variety of health services utilization studies
[14]. This comprehensive model of the demand for health
services was used in this study to identify independent
variables likely to influence essential medicines and health
supplies utilisation at the health facilities in the districts
and hence expenditure. The assumption is that since they
determine utilisation of health services by the population,
the identified independent variables influence the gener-
ated pharmaceutical expenditure as a result of utilization
of the health services.
The model posits that health services use is broadly
determined by societal factors, health services system
factors and individual or population factors. Individual
or population factors are categorized as predisposing
factors, need, and enabling factors. Predisposing factors
pertain to socio-demographics and include age, sex,
marital status, education, race/ethnicity, occupation; as
well as a set of beliefs (e.g. attitudes toward health ser-
vices, knowledge about disease, and values). Enabling
factors are those that support or impede health care ser-
vice use (e.g. income, type of health insurance); and also
encompass family and community resources and accessi-
bility of those resources. Need includes individuals’ per-
ceived and evaluated functional capacity, symptoms, and
general state of health. Specifically, Andersen’s model as-
sumes that individuals’ use of services is a function of
their predisposition to use services (predisposing fac-
tors), factors that support or impede use (enabling fac-
tors), as well as their need for health care (illness level).
According to Andersen, patients’ illness level (represent-
ing the need factor) is considered as the major determin-
ant of health care utilization.
The model has been widely used in a variety of health-
care utilization studies. In a RAND study, Kubrin used
Andersen’s model to develop and test predictive expecta-
tions about the role of health insurance in the use of
hospital and physician services [15]. Chen and Chang
used the model to construct independent variables to
investigate factors associated with prescription drug
expenditures among children based on the medical ex-
penditure panel survey [16]. Chern, Wan, and Begun
used the model to examine the relative importance of
determinants in predicting future use of dental health
services among a nationally representative sample of pa-
tients with HIV [17]. Kim and Kim employed the model
to estimate future demand for institutional long-term care
by Koreans [18]. Galbraith, Wong, Kim, and Newacheck
used Andersen’s model to select predisposing, enabling,
and need variables as independent variables that could
affect health care use and expenditures in a multivariate
analysis [19]. Roy and Madhavan used the model to de-
velop an explanatory model for state Medicaid per capita
drug expenditures in United States [20]. Heider et al. also
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employed the model to analyze health care costs in the
German elderly population [21]. No published research,
however, was found that used this model to study pharma-
ceutical expenditure in Uganda.
Variables and data collection
Andersen’s model of health services utilisation was used
as the operational framework for identification of vari-
ables in this study (Fig. 1). A list of the study variables,
their descriptions, measurements, and sources is pre-
sented in Table 1.
Like in many studies, a possible study approach would
have been to choose just one way of expressing pharma-
ceutical expenditure and then go ahead to estimate the
regression equation [5–7]. We however took the ap-
proach of specifying a different equation for each way of
expressing pharmaceutical expenditure, just like some
other studies [8, 10].
Thus, the dependent variable; pharmaceutical expend-
iture by all facilities in the district; was measured in
several ways as below:
 Total Primary Health Care Pharmaceutical
Expenditure; PHCPETotal: Value in UGX of
pharmaceuticals supplied by NMS to health facilities
in each district in one financial year
 Primary Health Care Pharmaceutical Expenditure
per capita; PHCPECapita: Average value in UGX of
pharmaceuticals supplied by NMS to health facilities
in each district in one financial year per district
inhabitant based on projected 2012 district
population
 Primary Health Care Pharmaceutical Expenditure
per outpatient visit; PHCPEVisit: Average value in
UGX of pharmaceuticals supplied by NMS to health
facilities in each district in one financial year per
reported number of outpatient department (OPD)
visits in PHC health facilities in the district during
the financial year
 Primary health care Pharmaceutical expenditure per
PHC health facility; PHCPEFacility: Average value in
UGX of pharmaceuticals supplied by NMS to health
facilities in each district in one financial year per
reported number of total PHC facilities in the
district
Consent from patients was not required, as this study
reports expenditures at the district level not at the patient
level. Data on the value of pharmaceuticals supplied by
NMS to health facilities in each of the 87 randomly se-
lected districts in Uganda for a one year period was ob-
tained from MOH for FY 2011/2012 (July 1 2011-June 30,
Fig. 1 Conceptual framework. Modified Andersen’s model: Operational framework for identification of variables. Each box represents a construct
which is described/measured by identified variables mentioned in the bullets. A complete list of variables their descriptions and measurement is
presented in Table 1
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Table 1 Description of study variables
Variable type Variable Description Measurement Data source
Predisposing factors DISTPOP District Population Total projected district population,2012 UNBS
PERCFEM District Female Population Percentage of Female district population, 2012 UNBS
Enabling factors RURALPOV Rural poverty Percentage of rural district population below poverty
line, 2005
NHS, 2005
HDI Human Development Index Composite index generated from life expectancy,
education attainment (adult literacy and gross
enrolment) and Gross Domestic Product per capita
UDHR, 2007
HPI Human Poverty Index; Index generated from measures of a long and healthy
life (probability at birth of not surviving to age 40);
Knowledge (adult illiteracy rate) standard of living
(% of without sustainable access to an improved
water source and % of children under-weight for age).
UDHR, 2007
URBANISATION Urbanization level Percentage of district considered to be urban NC, 2002
LABOURABSRATE Labour Absorption Rate Percentage of population of working age (15–65) who
are employed
NC 2002
LITRATETotal Total Literacy Rate Percentage of the population age 15 and above who
can, with understanding, read and write a short,
simple statement on their everyday life.
SUPR, 2008
LITRATEFemale Female Literacy Rate Percentage of the Female population age 15 and
above who can, with understanding, read and write
a short, simple statement on their everyday life.
SUPR, 2008
LITRATEMale Male Literacy Rate Percentage of the Male population age 15 and above
who can, with understanding, read and write a short,
simple statement on their everyday life.
SUPR, 2008
DISTAGE District Age Whether it’s a newly created district or not. = 1 if Yes;
=0 if Not
MOH APR 2011/12
DISTACCESS District accessibility Whether the district is characterized by MOH as hard
to reach or not. =1 if Yes; =0 if Not
MOH APR 2011/12
Need for health Care DPT3COVER Immunisation coverage Percentage of children fully immunized against
Diphtheria, Pertusis & Tuberculosis
MOH APR 2011/12
OPDCAPITA Outpatient attendance Outpatient attendance per capita MOH APR 2011/12
Policy factors TA Technical assistance Availability of donor funded Technical Assistance to
the district for Pharmaceutical Management: 1 if Yes;
=0 if No
SURE
ACCESSWATER Access to drinking water Percentage of district population with access to Safe
drinking Water
SUPR, 2008
LATCOVERAGE Latrine Coverage Percentage of households with latrine SUPR, 2008
Health care resources HFGOVTOT Government Health facilities Total Number of Government Health facilities in the
district (excluding hospitals)
MOH FIR, 2012
HOSPTOT General Hospital services Total Number of general Hospitals, both government




Total Number of Non Government Organization (NGO)
health facilities in the district
MOH FIR, 2012
RRHAVAIL Referral Hospital services Availability of Regional Referral hospital in the district:
Yes = 1 No = 0
MOH APR 2011/12
PERCHCII Health centre IIs Percentage of government health facilities that are HC II MOH FIR, 2012
PERCHCIII Health centre IIIs Percentage of government health facilities that are HC III MOH FIR, 2012
PERCHCIV Health Centre IVs Percentage of government health facilities that are HC IV MOH FIR, 2012
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2012). The data excluded pharmaceuticals supplied to dis-
trict, regional and national referral hospitals since these
are considered secondary and tertiary health care facilities.
It also excluded data on centralized budget lines for phar-
maceuticals that are mainly donor funded. These include
artmesinin based combination therapies (ACTs) for Mal-
aria; antiretrovirals (ARVs) and tuberculosis supplies; re-
productive and maternal health supplies; commodities for
health emergencies and vaccines for immunizations.
The independent variables were identified as:
 policy variables that capture information on
interventions to improve pharmaceutical
management in the district and programs aimed at
improving health status of the district population
 health care resource variables that describe access to
health services
 predisposing variables that describe demographic
characteristics of district population
 enabling resources variables that describe factors
that facilitate or impede the ability of the district
population to seek health care
 need for health care variables that describe demand
for health care or factors that influence health status
of the district population (e.g. immunization
coverage)
Data for the independent variables was collected from
various government data bases and reports (Table 1).
Study sample
A random sample of 87 districts was selected from the
112 districts that were operational in Uganda during the
2011/2012 financial year.
Analysis methods
The unit of analysis was the district. We used IBM SPSS
Statistics Version 20 to perform univariant descriptive
analysis to ascertain the shape of the distribution of each
variable and to discover existence of outliers. Summary
statistics (maximum, minimum, mean, standard devi-
ation) were used for this analysis. We also performed
bivariant descriptive and inferential analysis to measure
association between study variables and to compare
means between groups of districts. For this analysis,
Pearson’s coefficient and tests of equality of means were
used. Finally, we performed econometric analysis using
step wise multiple regression (with a stepping method
criteria of probability of F-to enter of 0.05 and probabil-
ity of F-to remove of 0.10) to estimate parameters of
various regression models. This was done by estimation
of ordinary least squares (OLS) and hypothesis tests of
the value coefficients. We run both linear-linear and log-
linear models for each definition of pharmaceutical ex-
penditure in order to select the model with the best fit.
Table 2 shows the variables used in the multiple linear
regression analysis to determine variations in pharma-
ceutical expenditure among the study districts.
Results and discussion
Results
Before performing the regression analysis, we conducted
an independent samples t-test in order to assess the null
hypothesis of no difference in pharmaceutical expend-
iture between groups of districts for all the dichotomous
variables in our data set. The results are shown in
Table 3.
The null hypothesis of no difference in total primary
health care pharmaceutical expenditure among districts
was rejected for districts with a regional referral hospital,
newly created districts and districts with external tech-
nical assistance for pharmaceutical management (P <
0.05). The null hypothesis of no difference in primary
health care pharmaceutical expenditure per health facil-
ity was only rejected for districts with a regional referral
hospital (P < 0.05). The null hypothesis of no difference
in primary pharmaceutical expenditure per OPD visit
between districts was only rejected for newly created
districts. However, the null hypothesis of no difference
in primary health care pharmaceutical expenditure per
capita between districts was not rejected for all the vari-
ables considered (P > 0.05).
We run various models (including log transformations)
for each dependent variable (definition of pharmaceutical
Table 1 Description of study variables (Continued)
STAFFSTRENGTH Staff strength Percentage of approved staff posts filled MOH APR 2011/12
HFACCESS Health facility accessibility Percentage of the district population that live within
5 km to a health facility
SUPR, 2008
UHDR-Uganda Human Development Report, 2007
SUPR-State of the Uganda Population Report; 2008
MOH-FI-Ministry of Health Facility Inventory Report, 2012
NHS-National Household Survey, 2005
MOH ARP-Ministry of Health Annual Performance Report, 2011/2012
SURE-Securing Ugandan’s Right to Essential Medicines Project Report 2011
NC-National Census; 2002
UNBS-Uganda National Bureau of Statistics
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expenditure) using step wise multiple linear regression
analysis. Table 4 shows the selected models (based on
Adjusted R2) for each definition of pharmaceutical ex-
penditure. Both linear-linear and log-linear models are
presented. All the models were significant over all (P <
0.01). The explanatory power of the models ranged from
51 to 82 %.
It is important to note that in this case, we cannot
compare the different models based on the adjusted R2
since the models had different definitions of primary
health care expenditure (dependent variable). Instead the
adjusted R2 should only be interpreted as the variation
in the specified primary health expenditure (e.g. total
pharmaceutical expenditure or per capita pharmaceutical
expenditure) that is explained by the variables in the
model.
The model (Model 1) based on total primary health care
pharmaceutical expenditure (PHCPETotal) explained about










PHCPETotal PHCPEcapita PHCPEVisit PHCPEFacility
Dependent Variable
PHCPETotal 86476 951622 326787.04 194122.894
PHCPECapita 0.33 2.21 1.1034 0.47168
PHCPEVist 0.33 4.46 1.1034 0.57175
PHCPEFacility 6974.01 50863.8 13039.4179 5382.5054
Explanatory Variables
Predisposing Factors
POPTOT 54000 1723300 316959.77 217044.77 .672** −.323** −0.16 .520**
PERCFEM 0.4 0.55 0.506 0.01888 .251* −0.164 −0.011 0.165
Enabling Factors
RURALPOV 7.74 % 85.56 % 38.61 % 17.73 % −0.118 −.318** −.305** −.315**
HDI 0.292 0.644 0.53572 0.060393 0.161 0.085 0.071 .260*
HPI 9.6 65.3 30.345 8.5006 −0.081 0.12 0.015 −.250*
LABOURABSRATE 16.30 % 70.70 % 52.95 % 0.008 0.034 0.062 −0.106
URBANISATION 1.10 % 100.00 % 8.19 % 11.34 % 0.211 −0.148 −0.193 .607**
LITRATETotal 0.80 % 93.70 % 65.05 % 14.63 % .264* 0.061 0.146 .275**
LITRATEFemale 0.80 % 92.20 % 57.16 % 15.74 % .269* 0.105 0.198 .323**
LITRATEMale 14.80 % 95.40 % 74.46 % 12.53 % 0.208 0.19 0.135 .250*
Need for Health Care
OPDCAPITA 0 3.4 1.127 0.5194 0.181 .455** −.460** −0.014
DPT3COVER 0.00 % 100.00 % 82.13 % 24.28 % −0.021 0.164 0.032 0.109
Policy Factors
ACCESSWATER 14.60 % 97.60 % 56.75 % 16.36 % 0.058 −.296** −0.141 0.129
LATCOVERAGE 9 % 98 % 67.96 % 18.23 % .222* 0.101 −0.007 0.152
Health Care resources
HFGOVTOT 7 88 26.2184 15.49375 .839** 0.179 −0.041 −0.183
HOSPTOT 0 28 1.36 3.118 .411** −0.126 −0.189 .690**
HFNGO 0 31 7.21 6.486 .576** −0.044 −0.059 .347**
PERCHCII 0.19 0.85 0.5731 0.15026 0.081 0.053 −0.034 −.497**
PERCHCIII 0.12 0.7 0.3594 0.13804 −0.093 −0.084 0.009 .362**
PERCHCIV 0 0.21 0.0675 0.04229 0.015 0.087 0.089 .583**
STAFFSTRENGTH 19.00 % 86.60 % 54.76 % 13.94 % 0.117 −0.142 −0.157 0.099
HFACCESS 43.70 % 96.50 % 69.85 % 11.06 % 0.193 0.133 −0.004 .266*
*Correlation is significant at the 0.05 level (2-tailed)
**Correlation is significant at the 0.01 level (2-tailed)
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82 % of the observed variation is total primary health care
expenditure among the study districts (Adjusted R2 =
0.821). Apart from the constant, all the predictor variables
in this model were found to be significant (P < 0.01). They
include one predisposing factors variable (POPTOT) and
three health care resources variables related to the number
(HFGOVTOT) and composition of health facilities in the
district (PERC HC II and PERCHC IV). Apart from per-
centage of Health Centre IIs (PERCHCII) which has a
negative coefficient, all the other variables have a positive
coefficient indicating that an increase in these variables
leads to an increase in total pharmaceutical expenditure.
For example, an increase in the total district population of
1,000 would leads to an increase of 226 UGX in the dis-
trict’s total primary health care pharmaceutical expend-
iture, all other factors remaining constant. Likewise, an
increase in the total number of government health facil-
ities by one would lead to an increase of UGX 9970.501 in
the district’s total primary health care pharmaceutical
expenditure, all other factors remaining constant.
The log-linear model for Total Pharmaceutical expend-
iture explains about 80 % of the variation in the logarithm
of total pharmaceutical expenditure among the study dis-
tricts (Adjusted R2 = 0.79). Unlike the linear model which
contains only pre-disposing and health care resource
variables, the log-linear model contains two need for
health care variables (DPT3COVER and OPDTOTAL),
one enabling variable (URBANISATION) and two health
care resources variables (HFGOVTOT and HCIITOT)
and hence can be considered a more balanced model.
Apart from the variable related to immunisation coverage
(DPT3COVER) and urbanisation (URBANISATION) all
other variables in the model are significant (p < 0.01) The
Urbanisation variable and Total number of Health centre
IIs variable have a negative coefficient indicating that an
increase in these variables results in a decrease in ob-
served pharmaceutical variable. For example a 1 % in-
crease in the percentage of the district considered to be
urban would lead to a decrease of 1 % decrease in the ob-
served total pharmaceutical expenditure all other factors
remaining constant. All other variables in the model had a
positive coefficient indicating that an increase in these var-
iables results in an increase in the observed total primary
health care pharmaceutical expenditure.
Model 8; the log-linear model based on primary health
care pharmaceutical expenditure per OPD visit explained
about 56 % of the observed variation in the logarithm of
primary health care expenditure per OPD visit in the
study districts (Adjusted R2 = 0.562). Apart from the con-
stant, all the predictor variables were found to be signifi-
cant (p < 0.05). They include one need for health care
variable (OPDCAPITA), and four enabling factors variables
(RURALPOV, HPI, DISTACCESS and LITRATETOT).
The OPDCAPITA and RURALPOV variables have a
Table 3 Comparison of the means of indicators of pharmaceutical expenditure (‘000) according to levels of dichotomic variables
Availability of RRH (RRHAVAIL) Yes (n = 13) Std deviation No (n = 74) Std deviation Means difference t Sig. (2 tailed)
PHCPETotal 566434.88 147749.606 284686.74 169652.114 −281748.144 −5.619 0.000
PHCPECapita 1.1587 0.35773 1.1159 0.42920 −0.04274 −0.338 0.736
PHCPEVist 0.9020 0.25030 1.1398 0.60613 0.23780 1.388 0.169
PHCPEFacility 16062.9092 10805.53931 12508.2640 3608.78774 −3554.64519 −2.247 0.027
Newly created district (DISTAGE) Yes (n = 23) Std deviation No (n = 64) Std deviation Means difference t Sig. (2 tailed)
PHCPETotal 190402.76 78370.452 375800.14 200163.186 185397.383 4.312 0.000
PHCPECapita 1.1484 0.41230 1.1129 0.42244 −0.03546 −0.347 0.729
PHCPEVist 1.3383 0.86995 1.0214 0.40019 −0.31689 −2.294 0.024
PHCPEFacility 12958.6832 4150.29242 13068.4319 5790.50282 109.74865 0.083 0.934
Hard to reach district (DISTACCESS) Yes (n = 18) Std deviation No (n = 69) Std deviation Means difference t Sig. (2 tailed)
PHCPETotal 281134.11 147940.892 338696.50 203694.745 57562.390 1.122 0.265
PHCPECapita 1.2578 0.52717 1.0870 0.38084 −0.17081 −1.558 0.123
PHCPEVist 1.2199 0.58504 1.0764 0.56955 −0.14350 −0.904 0.369
PHCPEFacility 11270.8536 3246.31591 13500.7825 5741.22578 2229.92887 1.579 0.118
Availability of TA for Pharmaceutical
Management (TA)
Yes (n = 34) Std deviation No (n = 53) Std deviation Means difference t Sig. (2 tailed)
PHCPETotal 413249.53 194700.748 271320.53 173902.561 −141929.001 −3.544 .001
PHCPECapita 1.1870 0.42871 1.0808 0.40914 −0.10624 −1.160 .249
PHCPEVist 1.0605 0.48092 1.1320 0.62806 0.07155 0.563 0.575
PHCPEFacility 12533.7598 3121.21665 13363.8023 6438.73667 830.04242 0.700 0.486
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negative coefficient indicating that an increase in these
variables results in a reduction in the pharmaceutical
expenditure per OPD visit. The other variables all have a
positive coefficient indicating that an increase in these
variables results in an increase in the primary health care
pharmaceutical expenditure per OPD visit. For example,
according to this model, a district characterised by MOH
as hard to reach would have a primary health care
pharmaceutical expenditure per OPD visit of UGX 0.384
higher than a district not characterised as hard to reach,
all factors remaining constant.
The model based on primary health care pharmaceut-
ical expenditure per capita (Model 5) explained about
50 % of the observed variation in per capita primary
health care pharmaceutical expenditure among the study
districts (Adjusted R2 = 0.513). The model comprised of
one health care need variable (OPDCAPITA), and four
enabling factors variable (RURALOV, HPI, DISTACCESS
and LITERATEMale). Apart from the constant, coeffi-
cients for all the other predictor variables for this model
were significant (P < 0.05). The constant and RURALPOV
had a negative coefficient, indicating that an increase in
the percentage of rural district population below poverty
line leads to a decrease in primary health care pharma-
ceutical expenditure per capita. For example, a 1 % in-
crease in the proportion of a district’s rural population
below the poverty line would lead to a decrease in primary
health care pharmaceutical expenditure per capita of UGX
0.012, all other factors remaining constant. The coeffi-
cients for all the other variables were positive indicating
that an increase in these variables would lead to an in-
crease in primary health care pharmaceutical expenditure
per capita. For example, a district that is characterised by
MOH as hard to reach would have a per capita pharma-
ceutical expenditure of UGX 0.362 higher than a district
that is characterised as not hard to reach, all other factors
being constant.
For primary health care pharmaceutical expenditure per
health facility, the selected log-linear model (Model 4)
comprised of two health care resources factor variables
Table 4 Multiple regression models explaining pharmaceutical expenditure
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8
PHCPETotal InPHCPETotal PHCPEFacility InPHCPEFacility PHCPECapita In. PHCPECapita PHCPEVisit InPHCPEVisit
Constant 43478.008 11.417* 13657.011* 9.467* −0.500 −1.168* 3.061* −0.372
POPTOT 0.226*
OPDCAPITA 0.320* 0.345* −0.580* −0.465*
OPD TOTAL 0.00000056*
DPT3COVER 0.003 36.566* 0.003*
RURALPOV −0.012* −0.009* −0.016* −0.010*
HPI 0.026* 0.021* 0.020*
LABOURABSRATE −91.918* −0.007* −0.014
URBANISATION −0.014 −122.072 −0.010






PERCHCII −159186.625* −9569.914* −0.776*
PERCHCIII
PERCHCIV 31533.892* 2.467*
DISTACCESS 0.362* 0.341* 0.461* 0.384*
N 87 87 87 87 87 87 87 87
F 99.325 64.453 15.064 15.801 18.067 15.655 13.543 21.764
R2 0.892 0.809 0.547 0.558 0.543 0.507 0.413 0.589
Adjusted R2 0.821 0.797 0.510 0.523 0.513 0.475 0.382 0.562
Significance 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
*(p < 0.01)
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(PERCHCIV, PERCHCII), one need for health care
factors variable (DPT3COVER) and three enabling
factors variables (URBANISATION, LITRATETOT,
LABOURABSORPTION ). Together, these factors ex-
plain 52 % of the observed variation in the primary health
care pharmaceutical expenditure per health facility in the
study districts (Adjusted R2 = 0.522). All predictor vari-
ables in this model and the constant were significant (p <
0.05). The variables PERCHCII, URBANISATION, and
LABOURABSRATE had a negative coefficient indicating
that an increase in these variables leads to a decrease in
primary health care pharmaceutical expenditure per dis-
trict health facility. The other variables had a positive co-
efficient indicating that an increase in these variables
would lead to an increase in primary health care pharma-
ceutical expenditure per district health facility. For ex-
ample, a 1 % increase in the district DPT3 coverage
would result in a 0.3 % increase in the primary health
care pharmaceutical expenditure per district health facil-
ity all other factors remaining constant.
Discussion
This study aimed at identify predictors of primary health
care pharmaceutical expenditure by districts in Uganda
and to establish explanatory models of such expenditure
based on the potential influence of the identified predic-
tors. The established explanatory models would be use-
ful for rough estimation of potential national primary
health care pharmaceutical budget based on previous
expenditure and to guide budget setting discussions
between ministry of Finance and Ministry of Health.
The models would also be useful in improving equity by
allocating any set budget among the various districts by
the government of Uganda based on need. Like in many
studies, a possible study approach would have been to
choose just one way of expressing pharmaceutical ex-
penditure and then go ahead to estimate the regression
equation [5–7]. We however took the approach of speci-
fying a different equation for each way of expressing
pharmaceutical expenditure, just like some other studies
[8, 10]. This is important because whereas one model
may be useful in predicting future expenditure, it may
not be ideal for guiding budget allocation especially if
the variables in the model are not related to need, since
ideally this should be the basis for budget allocation.
The variables in the model for total primary health
care pharmaceutical expenditure explain about 82 % of
the observed variation in total pharmaceutical expend-
iture among the study districts; and hence the model
can be accepted as a good fit for the data. However, this
model contains only health care resources variables re-
lated to the number and composition of health facilities
in the district. The log-linear model for Total Pharma-
ceutical expenditure whose variables explain about 80 %
of the observed variation in total pharmaceutical ex-
penditure is a more balanced model since in addition to
health care resource variables, it also contains need and
one enabling factor variable. This balanced model works
acceptably well and would be useful for predicting total
pharmaceutical expenditure.
Based on the above argument and the study data, the
proposed model for predicting total district primary phar-
maceutical expenditure in Uganda is shown in Table 5.
This model could be used by MOH for rough estima-
tion of future expenditure and to guide negotiations with
Ministry of Finance for budget setting.
The proposed prediction model comprises of two
health care resources variables related to availability and
composition of health facilities in the district. As ex-
pected, an increase in the available number of health fa-
cilities is predicted to increase health care utilisation and
health expenditure, hence the positive coefficient for the
variable total government health facilities in the district.
The other variable relate to the breakdown of the avail-
able health facilities in terms of level of care. Health
Centre IIs are the lowest level of care, with few staff and
limited ability to address a wide range of health condi-
tions. A district with a higher number of Health Centre
IIs among its health facilities is expected to have a lower
total pharmaceutical expenditure compared to a district
with a lower number of Health Centre IIs, all other fac-
tors being constant. This explains the negative coeffi-
cient for the variable number of health centres IIs in the
district. As expected, the variable related to health care
utilisation, total OPD attendance has a positive coeffi-
cient; an increase in total district health care utilisation
is expected to increase total pharmaceutical expenditure.
The negative coefficient for urbanisation may be related
to the fact that urban centres have more private health
care facilities which draw away patients from public
sector health facilities leading to a reduction in the ob-
served total pharmaceutical expenditure in the public
sector health facilities.
Different approaches have been used to predict
Pharmaceutical expenditure and to guide budget setting,
Table 5 Proposed model for predicting total primary health
pharmaceutical expenditure by districts in Uganda
Variables Coefficient Standard error Student’s t Significance
Constant 11.417* 0.134 85.441 0.000
OPDTOTAL 0.00000056* 0.000 3.085 0.003
DPT3COVER 0.003 0.001 2.277 0.026
URBANISATION −0.014 0.005 −2.569 0.012
HFGOVTOT 0.053* 0.007 7.677 0.003
HCIITOT −0.39* 0.009 −4.461 0.000
Dependent Variable: InPHCPETotal n = 87; R2 = 0.809 Adjusted R2 = 0.797;
F = 64.453 Significance =0.000
*(p < 0.01)
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including use of morbidity data and use of diagnosis and
pharmacy claims data [22–26]. The predictive model
developed in this study uses historical pharmaceutical
expenditure data. There are a number of problems using
historical costs as a basis for budget setting. Besides the
lack of guarantee that the current expenditure is efficient
and the possibility of manipulation by health managers
who may have the incentive to increase their current
expenditure with the expectation of larger budgets in
the future, for better accuracy, adjustments may need to
be made for the impact of certain contextual factors not
included in the model. The predicted pharmaceutical ex-
penditure using this model could for example be refined
by adjusting for factors likely to increase or decrease fu-
ture utilisation and expenditure such as new drugs to be
introduced in the health systems or new treatment
guidelines to be introduced [26].
A key strength of this study is that uses various factors
in Andersen’s health services utilisation model adapted to
data in a developing country context to predict primary
health pharmaceutical expenditure using readily available
pharmaceutical procurement data. Most prior studies of
this nature have focused on a single category of predictors
(e.g. need, demographics or policy factors) and are mainly
in developed country contexts that have medicines pro-
vided through health insurance [9, 17, 19, 20]. Addition-
ally, unlike this study, most studies have used individual
pharmaceutical expenditure data collected through sur-
veys or from individual medical records [11, 12].
Findings from this study could have important applica-
tions for the government of Uganda regarding setting
and allocating primary health care pharmaceutical bud-
gets. The log-linear model based on total primary health
care pharmaceutical expenditure would for example be
used to predict future total district primary health care
pharmaceutical expenditure based on any plans the gov-
ernment may have for the district (e.g. increasing the
number of health facilities, upgrading facilities etc.). The
predicted total district PHC pharmaceutical expenditure
for all districts would then be added together to predict
the potential national PHC pharmaceutical expenditure.
This would then be used by MOH to negotiate and set
the national PHC pharmaceutical budget with Ministry
of Finance.
The log-linear model based on total primary health
care pharmaceutical expenditure may however not be
ideal for allocating the set national primary health
pharmaceutical budget among the various districts based
on the needs of the population. This is because this
model relies mainly on enabling and health care
resources variables (HFGOVTOT, HC II TOT, and
URBANISATION).
Ideally, need should be the major determinant of health
care utilisation and should guide resource allocation.
Based on this argument, the model of pharmaceutical ex-
penditure per capita (Model 5) which contains need and
health care pre-disposing variables would be useful for
identifying factors to be considered in allocating the na-
tionally set PHC pharmaceutical budget among districts
once received by MOH based on negotiations conducted
with Ministry of Finance using the log linear model based
on total pharmaceutical expenditure.
Based on this model, proposed variables to be consid-
ered in allocating the set budgets among districts include
the following need and pre-disposing health variables:
OPD capita attendance, percentage of rural population
below poverty line 2005, Male Literacy rate, Whether a
district is characterised by MOH as difficult to reach or
not and the Human poverty index.
The outpatient department attendance per capita
(OPDCAPITA) variable is a direct reflection of demand
for health care and therefore need. The expenditure gen-
erated from this demand is geared towards meeting the
expressed need. The higher the demand the higher the
expenditure. This calls for a higher budget allocation.
This is supported by the positive coefficient of this vari-
able in the model.
The model includes four enabling factor variables two
socioeconomic variables which are the percentage of the
district rural population below the poverty line 2005
(RURALPOV) and the Human Poverty Index (HPI),
Male Literacy rate and whether a district is characterised
by MOH as hard to reach or not. One would expect that
the higher the percentage of rural poor living below the
poverty line, the higher the incident of diseases and
hence the higher the observed pharmaceutical expend-
iture, justifying a higher budget allocation. In such a
situation, one would expect the variable RURALPOV to
have a positive coefficient, contrary to what is observed
in this study. It is also possible that given their poverty
status, the poor may not be able to access health care
hence leading to low expenditure in an area where the
poor are the majority [22]. Such a scenario would lead
to the RURALPOV variable having a negative coefficient
as observed in this study. This could however be an indi-
cation of inequity in the current allocation which needs
to be investigated.
The HPI measures deprivations in four dimensions: a
long and healthy life-defined by vulnerability to death at
a relatively early age- as measured by the probability at
birth of not surviving to age 40; knowledge- defined by
exclusion from the world of reading and communica-
tions- as measured by the percentage of adults (aged
16–65) lacking functional literacy skills; a decent stand-
ard of living, as measured by the percentage of people
living below the income poverty line (50 % of the median
adjusted household disposable income); and social exclu-
sion as measured by the rate of long-term unemployment
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(12 months or more) [27]. The closer the index is to 0, the
better, indicating the absence of human poverty; while the
closer it is to 100, the more deprived the population is.
The selected model suggests that more deprived districts
should be given a higher budget allocation since one
would expect a more deprived population to have higher
health needs and hence higher pharmaceutical expend-
iture and higher budget allocation.
One variable which does not appear in the log –linear
prediction model based on the total pharmaceutical ex-
penditure, but appears in the allocation model that is
based on primary health care pharmaceutical expend-
iture per capita is the variable related to whether a dis-
trict is considered by MOH to be a hard to reach district
or not (DISTACCESS). In the allocation model (Model 5)
the variable is significant and has a positive coefficient.
This suggests that districts that are characterized by MOH
as hard to reach have a higher expenditure and should be
allocated higher primary health care pharmaceutical bud-
gets than other districts. MOH characterizes districts as
hard to reach based on geography, among other factors.
Geography can play an important role in influencing both
individual health status and access to health services [28].
It is plausible that being hard to reach might affect the
need for pharmaceuticals; for example in an area that is
geographically distant, there may be an optimal substitu-
tion towards greater pharmaceutical use, since pharma-
ceuticals are typically more transportable than most other
types of resource. Including this variable in the proposed
allocation formulae offer a means to balance geographic
disparities. However, it is difficult to differentiate legitim-
ate factors related to geography that influence need for
pharmaceuticals from spurious, supplier induced dispar-
ities in expenditure [28].
Limitations
The findings of this study could have been influenced by
the study limitations. Some of the data for the explana-
tory variables was based on past national surveys and
have not been updated. For example, the Human Poverty
Index data used is based on the national survey con-
ducted in 2007, and the rural poverty data used is for
2005. The assumption that these indicators have re-
mained constant over the period in all districts of the
country may not be entirely true. Any changes that have
happened in these variables may result in either under
or over estimation of the various parameters of the
models due to inaccurate measurement of the variable.
Also, through re-districting, many new districts have
been created over the period by breaking up large districts
into smaller ones. Data for new districts was missing for
variables obtained from national surveys conducted before
the districts were created. Gaps in data were filled by allo-
cating the same variable value to a new district as the
parent district. Whereas this was the best approach to fill
gaps in the circumstances, it assumes homogeneity among
all counties in the district, which may not necessarily be
true.
The study did not take into account centralized
pharmaceutical budget lines which cover pharmaceuti-
cals for Malaria, HIV/AIDS, Family Planning and Tuber-
culosis. These “program” medicines are mainly funded
by donors and more funds are used for their procure-
ment compared to essential medicines which were con-
sidered in the study. It is estimated that 60 % of health
commodity financing in Uganda is donor dependent and
focused on the program commodities which account for
a large portion of the total Pharmaceutical expenditure
in each district [3]. Specifically, ACTs are one of the
most widely prescribed medicines since Malaria is the
leading cause of OPD attendance in health facilities.
However, spending on ACTs was not included in the
study and this may have affected the results. Also, the
results of this study may be subject to omitted variable
bias due to the fact that data on district disease preva-
lence was not included as one of the study variables. Ob-
served differences in expenditure between districts could
be explained by differences in needs caused by differ-
ences in disease burden.
The value of Pharmaceuticals procured by districts
from NMS was used as proxy for Pharmaceutical ex-
penditure. This assumes that all the Pharmaceuticals
procured during the financial year were dispensed and
that the facility started with no stock at the beginning of
the financial year. Although high stock out rates have
been reported in the public sector health facilities [29],
this assumption is unlikely to be true since health facil-
ities maintain some buffer stock for a number of com-
modities as per the national inventory management
guidelines. Using actual dispensing/pharmacy data from
health facilities would have been a better reflection of
actual pharmaceutical expenditure.
The study is based on Anderson’s model for acute care
and the focus is on PHC which is the lowest level of
care. At the macro level however, the evolution of
pharmaceutical expenditures is generally driven by the
entrance of new branded products and products going
off-patent (genericization of the market), ageing popula-
tions, the growing prevalence of chronic disease, the dis-
ease burden confronted with, the greater use of expensive
treatments and also the regulatory environment and cost-
containment strategies introduced by healthcare payers. A
key assumption of our study as underpinned by Andersen’s
model is that utilization of health services drives utiliza-
tion of pharmaceuticals and hence expenditures. As such
some of the earlier mentioned factors that drive evolution
of pharmaceutical expenditure at the macro level are out
of our study scope and data set. This however affects the
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transferability potential of the suggested prediction and al-
location models.
Conclusion
The log linear model for total PHC pharmaceutical
expenditure comprising of two need for health care
variables (DPT3COVER and OPDTOTAL), one enabling
variable (URBANISATION) and two health care re-
sources variables (HFGOVTOT and HCIITOT) is a bal-
anced model and has a high explanatory power. This
model would be useful for MOH in negotiating and set-
ting the national PHC pharmaceutical budget with Minis-
try of Finance. Although the proposed model adequately
explains total district PHC pharmaceutical expenditure, its
predictive value should be established as data for model
variables becomes available for subsequent years.
However, a key limitation of this model is that it relies
heavily on health care resources and enabling variables
according to Andersen’s model. As such it may not be
ideal for budget allocation to districts once the overall
national budget is set. For such an allocation, the model
based on pharmaceutical expenditure per capita would
be ideal since it contains more factors as identified by
the modified Andersen’s model. Specifically it includes
need for health factors (out patient department visit per
capita) which should ideally drive resource allocation if
equity is to be attained.
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